Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × Digoxin × Clear all

NCT00281021 2018-03-29

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Phase 2 Terminated

26 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung